logo
SocialPilot makes landmark exit: Swedish firm buys Ahmedabad IT company for Rs 400 crore; used by 13,000+ firms globally

SocialPilot makes landmark exit: Swedish firm buys Ahmedabad IT company for Rs 400 crore; used by 13,000+ firms globally

Time of India23-07-2025
Ahmedabad-based SocialPilot, a bootstrapped social media management platform, has been acquired by Sweden's group.one for over $50 million. This acquisition marks a significant exit for an Indian bootstrapped startup and a milestone for Gujarat's IT sector.
AHMEDABAD: A bootstrapped startup from the city has just made global waves. SocialPilot, a social media management platform used by over 13,000 businesses worldwide, has been acquired by Sweden-based tech firm, group.one, for over $50 million (over Rs 400 crore), say industry sources.
Co-founders Jimit Bagadiya and Tejas Mehta confirmed the acquisition, though the deal size remains officially undisclosed. The acquisition is being described as "one of the biggest exits by a bootstrapped startup in India" and "a landmark moment for Gujarat's IT sector", which has largely remained behind metros like Bengaluru and Pune in high-value acquisitions.
Started in 2014 with no outside investment, SocialPilot has grown steadily over the past decade into one of India's most successful self-funded tech ventures.
Group.one, which serves more than 2 million small and medium-sized businesses across 15 countries, said the acquisition will help deepen its reach in the social media marketing space.
You Can Also Check:
Ahmedabad AQI
|
Weather in Ahmedabad
|
Bank Holidays in Ahmedabad
|
Public Holidays in Ahmedabad
For Bagadiya and Mehta, the decision to sell was driven by a vision to scale. "We decided to sell our entire stake to Group.one," said Bagadiya, CEO. "My partner is based in the US, and after running SocialPilot for over a decade, we reached a stage where the business was profitable, growing steadily, and operating at scale.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Top Cardiologist Begs: Quit Eating Blueberries Before This Happens
Gundry MD
Learn More
Undo
But we also recognised that to unlock the next phase - expanding into new markets, deepening the product, and accelerating distribution - we needed stronger leverage, either through funding or a strategic partnership.
"
Interestingly, the tool was originally built for e-commerce sellers struggling to promote products on social media. "While working on e-commerce projects for clients in the US and Europe, we recognised that e-commerce sellers were unable to promote their products effectively on social media. So, we built SocialPilot. It evolved into a platform for marketing agencies and SMBs, helping manage, schedule, and analyse posts across platforms," he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Economic Times

time6 minutes ago

  • Economic Times

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'

Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead

Hans India

time9 minutes ago

  • Hans India

Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead

New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store